$INMB News

Manufacturing Progress Gives INmune Bio a Clearer UK Filing Path for Ebstrocel

INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027

INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar

INmune Bio Submits Final Pre-Marketing Authorization Application Package To UK MHRA For Ebstrocel For Recessive Dystrophic Epidermolysis Bullosa; Expects Full MAA Submission In Early February 2027, With Potential UK Approval In Mid-2027; Has Engaged U.S. Regulatory Advisors With Rare Disease Expertise To Prepare And Submit A Type B Meeting Request To FDA

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™

INmune Bio And Quantum Computing Inc. Partner To Use Quantum AI To Identify New Treatment Applications For Alzheimer’s Drug XPro

Full Transcript: INmune Bio Q2 2026 Earnings Call

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board

INmune Bio to Present at the H.C. Wainwright Global Investment Conference

INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

INmune Bio Submits Two Regulatory Packages To EMA For Ebstrocel: Application For Orphan Drug Designation And Scientific Advice Package To Streamline Upcoming MAA In Europe

INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript

INmune Bio (INMB) Q2 2026 Earnings Call Transcript

INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regulatory Wins and Strategic Focus ...

INmune Bio, Inc. Q2 2026 Earnings Call Summary

INmune Bio Q2 Earnings Call Highlights

INmune Bio (NASDAQ:INMB) Beats Q2 Loss Estimates but Shares Tumble on Business Update

INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress

INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th